3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
15
Neoplasms
8
cyclopia sequence
7
Prostatic Neoplasms
7
Polycystic Ovary Syndrome
5
Fatigue
5
Lung Neoplasms
4
Head and Neck Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Pain
3
Obesity
3
Neoplasm Metastasis
3
Multiple Myeloma
3
Leiomyoma
3
Vomiting
2
Urinary Bladder Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Neoplasms, Plasma Cell
2
Nausea
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Insulin Resistance
2
Infertility
2
Hyperandrogenism
2
Hematologic Diseases
2
Depression
2
Burkitt Lymphoma
2
Weight Loss
1
Interventions
rozanolixizumab
10
zilucoplan
8
efgartigimod alfa
8
Rituximab
7
Cyclophosphamide
7
telitacicept
6
fludarabine
6
eculizumab
5
Prednisone
5
ravulizumab
4
Pyridostigmine Bromide
4
Immunoglobulins, Intravenous
4
Hizentra
4
Tacrolimus
3
Mycophenolic Acid
3
HBM9161
3
Amifampridine
3
thymoglobulin
2
inebilizumab
2
Prednisolone
2
Exercise
2
tofacitinib
1
tocilizumab
1
talquetamab
1
satralizumab
1
sargramostim
1
rhoA GTP-Binding Protein
1
remibrutinib
1
prednylidene
1
iscalimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Myasthenia Gravis
×
Sugars
×
Clear all
NCT00995722
2017-06-02
EPITOME'
University of Miami
Phase 3
Terminated
11 enrolled
14 charts